Ocular Oncology Center, Galliera Hospital, Genoa, Italy.
Ophthalmologica. 2012;227(4):190-6. doi: 10.1159/000334401. Epub 2012 Jan 20.
To evaluate survival and clinical outcome for patients with a large uveal melanoma treated by either enucleation or proton beam radiotherapy (PBRT).
This retrospective non-randomized study evaluated 132 consecutive patients with T3 and T4 choroidal melanoma classified according to TNM stage grouping.
Cumulative all-cause mortality, melanoma-related mortality and metastasis-free survival were not statistically different between the two groups (log-rank test, p = 0.56, p = 0.99 and p = 0.25, respectively). Eye retention of the tumours treated with PBRT at 5 years was 74% (SD 6.2%). In these patients at diagnosis, 73% of eyes had a best-corrected visual acuity (BCVA) of 0.1 or better. After 12 and 60 months, BCVA of 0.1 or better was observed in 47.5 and 32%, respectively.
Although enucleation is the most common primary treatment for large uveal melanomas, PBRT is an eye-preserving option that may be considered for some patients.
评估接受眼球摘除术或质子束放射疗法(PBRT)治疗的大型脉络膜黑色素瘤患者的生存和临床结局。
本回顾性非随机研究评估了根据 TNM 分期分组的 132 例连续 T3 和 T4 脉络膜黑色素瘤患者。
两组患者的全因死亡率、黑色素瘤相关死亡率和无转移生存率无统计学差异(对数秩检验,p = 0.56、p = 0.99 和 p = 0.25)。接受 PBRT 治疗的肿瘤 5 年眼球保留率为 74%(SD 6.2%)。在这些患者诊断时,73%的眼睛最佳矫正视力(BCVA)为 0.1 或更好。在 12 个月和 60 个月时,BCVA 为 0.1 或更好的分别为 47.5%和 32%。
尽管眼球摘除术是大型脉络膜黑色素瘤最常见的主要治疗方法,但 PBRT 是一种保留眼球的选择,可考虑用于某些患者。